Details of the Drug Combination

General Information of Drug Combination (ID: DCLJJZL)

Drug Combination Name
Leuprolide ABIRATERONE
Indication
Disease Entry Status REF
Prostate Cancer Phase 2 [1]
Component Drugs Leuprolide   DM5XPIJ ABIRATERONE   DM8V75C
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Leuprolide
Disease Entry ICD 11 Status REF
Plasma cell myeloma 2A83.1 Approved [2]
Prostate cancer 2C82.0 Approved [3]
Endometriosis GA10 Investigative [2]
Leuprolide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leutinizing-hormone-releasing hormone (GNRH1) TT0ID4A GON1_HUMAN Activator [5]
------------------------------------------------------------------------------------
Leuprolide Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Thyroxine-binding globulin (SERPINA7) OTUYVTSU THBG_HUMAN Increases ADR [6]
Protein bric-a-brac 2 (bab2) OTNNK0KI BAB2_DROME Increases ADR [6]
------------------------------------------------------------------------------------
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [4]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Prostate Cancer DCHM8XH N. A. Phase 2 [8]
Newly Diagnosed Oligometastatic Prostate Cancer DCWFB6E N. A. Phase 2 [9]
Prostate Cancer DCC5P8T N. A. Phase 1 [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03043807) A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
2 Leuprolide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1175).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
5 Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
8 ClinicalTrials.gov (NCT02772588) AASUR in High Risk Prostate Cancer
9 ClinicalTrials.gov (NCT03298087) Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
10 ClinicalTrials.gov (NCT04194554) A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer